It remains in phase 3 as a once-daily oral regimen given alongside the company's non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine), which was approved by the FDA in 2019.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback